VANINOLOL - A NOVEL COMPOUND FOR THE TREATMENT OF GLAUCOMA AND ISCHEMIC RETINOPATHY

Vaninolol has been confirmed as a selective beta(1)-adrenergic blockin g agent. The new compound was studied for its effects on intraocular p ressure (IOP), the ocular blood now and the retinal function in this r eport. Vaninolol showed marked delay in IOP recovery demonstrating tha t the agent possessed an ocular hypotensive action. This effect is equ ipotent or slightly more active than L-timolol. In addition, effects o f vaninolol on the ocular blood flow of ocular hypertensive eyes were determined using the colored microspheres technique. It was found that vaninolol improved the ocular blood now in ciliary body and retina, b ut not in iris and choroid. Further, vaninolol is able to improve the b-wave recovery in electroretinography significantly, indicating that it is possible to develop a new agent for the treatment of ischemic re tinopathy.